1. Tahir H, Rahman N, Thilaganathan B, Nicolaides K. Levels and regulation of SHBG, Testosterone and Oestrogen in foetal serum.Abstract Medical Research Council, 1993
2. Tahir H, Thomas G, Sheerin N, Pattison JM, Goldsmith DJA. Successful medical treatment of acute bilateral emphysematous pyelonephritis. American Journal of Kidney Diseases, Vol 36, No 6, 2000: 1267-1270
3. Tahir H, Allard S, Jawed S. Spontaneous Hydropneumothorax in a man with rheumatoid arthritis. Rheumatology 2001; 40: 232-233
4. Tahir H, Herring R, Gendi N, Maddison V, Gordon T, Dasgupta B. Effectiveness and safety of anti-TNF therapy in clinical practice Experience from South Essex. Abstract, British Society of Rheumatology meeting April 2002
5. Farzaneh-Far R, Watkins J, Tahir H, Wykes F, Beynon H. Small vessel vasculitis with pulmonary aneurysms and silent myocardial infarction. Rheumatology 2003; 42(8):1022-4
6. Watkins J, Tahir H, Farzaneh-Far R, Wykes F, Beynon H. Jo-1 syndrome with associated poorly differentiated adenocarcinaoma. Rheumatology 2004; 43(3):389-90.
7. Tahir H, Isenberg D. Novel Therapies in Lupus Nephritis. Lupus 2005; 14(1):77-82.
8. Tahir H, Rohrer J, Bhatia A, Wegener B, Isenberg DA. Humanised anti CD 20 monoclonal antibody in the treatment of severe resistant systemic lupus erythematosus in a patient with antibody against rituximab. Rheumatology 2005 Apr; 44(4):561-62
9. Allen P & Tahir H, A case report of how easily malaria can be missed. J R Soc Med.2006; 99: 201-202
10. Tahir H & Iqbal Z. Do doctors who volunteer their services in disasters overseas do more harm than good? BMJ 2006;332:244
11. Irving KS, Sen D, Tahir H, Pilkington C, Isenberg DA..A comparison of autoimmune liver disease in juvenile and adult populations with systemic lupus erythematosus – A retrospective review of cases. Rheumatology. 2007;46(7):1171-3
12. Tahir H, Moore S, Ehrenstein MR. Comparison of anti-TNF therapy in Daily Practice. Rheumatology Abstract 2006
13. Shenker NG, and Tahir H . Vitamin D levels should not be included in the routine laboratory tests for screening patients with fibromyalgic symptoms. Rheumatology 2007 Abstract (322)
14. Cooney M, Doyle DV, Greenwood M, Hakim AJ, Shenker N, Tahir H. An audit of efficacy, side effects and withdrawals for Infliximab and Etanercept in the treatment of RA Rheumatology Abstract 2007
15. Greenwood M, Cooney M, Rooney M, Hakim AJ, Tahir H. A Retrospective Comparison of the Three Year Outcome of Etanercept and Infliximab for Rheumatoid Arthritis in Clinical Practice. Rheumatology 2008; 47(4): #136
16. Greenwood M, Cooney M, Rooney M, Hakim AJ, Tahir H. A Comparison of the Two Year Outcome of Etanercept as a First and Second Anti-TNF Alpha Agent in Clinical Practice. Rheumatology 2008; 47(4): #109
17. Cooney M, Greenwood M, Rooney M, Tahir H, Hakim AJ. 12 Months Experience of Etanercept in the treatment of Psoriatic Arthritis. Rheumatology 2008; 47(4): #227
18. Greenwood MC, Hakim AJ, Donnelly SP, Rooney MM, Tahir H. Comparing outcome for the first 12M of anti-TNF therapy in RA in a standard UK clinical practice. Greenwood MC, Hakim AJ, Donnelly SP, Rooney MM, Tahir H. Rheumatology, April 2009;48;i63 (114)
19. Greenwood MC, Donnelly SP, Rooney MM, Hakim AJ, Tahir H. 4yr outcome data in RA patients receiving either Etanercept or Inflixamab in standard clinical practice. Rheumatology, April 2009;48; i64(119)
20. Penn H, Greenwood MC, Hakim AJ, Donnelly SP, Tahir H. An audit of TB prophylaxis for anti-TNF traeted patients in secondarycare in East London- is the BTS guidance useful? Rheumatology, April 2009;48;i113(276)
21. Greenwood M, Farooqui O, Hakim AJ, Donnelly SP, Rooney M, Lanham JG, Tahir H. ANKYLOSING SPONDYLITIS AND ANTI-TNF a:EXPERIENCE IN CLINICAL PRACTICE POST 2008 NICE GUIDANCE. Rheumatology 2010:49;i51
22. Hasson R, Mulcahy V, Tahir H. Amlodipine poisioning complicated with acute non-cardiogenic pulmonary oedema .BMJ Case Reports Published 5 September 2011;2011:published online 5 September 2011, doi:10.1136/bcr.07.2011.4467
23. Iqbal Z, Tahir H. Common Sports related Infections. In Clinical Sports Medicine (McGraw-Hill Sports Medicine). Brukner P & Khan K. Chapter 56, 4th Edition, 2011
24. Housman L, Arden N, Schnitzer TJ, Birbara C, Conrozier T, Skrepnik N, Wei N, Bockow B, Tahir H, Hammond A, Bailleul F. Intra-articular hylastan versus steroid for knee osteoarthritis .Knee Surgery, Sports Traumatology, Arthroscopy February 2013
25. Donnelley S, Baird K, Ismail L, Greenwod M, Tahir H. The Ottawa ankle rules to prevent unnecessary radiology: experience in a busy emergency dept in the UK. Submitted emergency medical journal 2013
26. Tahir H, Donnelly S, Greenwood M. A Phase 4 pilot study to establish whether an intramuscular steroid injection is as effective as an intralesional steroid injection in the treatment of tennis elbow. Rheumatology 2013; i160, 276
27. Adshead R, Cambridge S, Donnelley S, Tahir H. Earl Inflammatory Back Pain Service to provide assessment, diagnosis and prompt treatment for patients with axial spondyloarthropathies. Rheuamtology 2013; i166, 292
28. Greenwood M, Baqai T, Cambridge S, Shaikh M, Rooney M, Donnelley S, Tahir H. Patient preferences for route of administration of Biologic therapies. Rheumatology 2013; i95; 104
29. Combe W, Fitzgerald O, Tahir H, Gaylord S, Williams T, Pederson R, Valhos B, Kotak S. Impact of Etanercept- Methotrexate withdrawl on patient reported outcomes in patients with early rheumatoid arthritis (PRIZE Trial). Arthritis & Rheumatology; abstract 2359
30. Casey G, Tierney C, Tahir H, Donnelley S, Bubbear J. Patient satisfaction with an associated teaching hospital clinical trial unit in north east London. Arthritis & Rheumatology; abstract 1925
31. Shaikh M, Tahir H. Septic Sacroilitis mimicking an Inflammatory spondyloarthropathy. Rheumatology, vol 53, Supp 1, i61, April 2014
32. Fattah Z, Tahir H, Ranganathan A, Bubbear J. Complete healing of traumatic multiple spinal fractures in a patient with Ankylosing Spondylitis who refused surgical intervention with teriparatide. Rheumatology, vol 53, Supp 1,i66, April 2014
33. Shaikh MF, Baqai TJ, Tahir H. Acute brachial neuritis following influenza vaccination. BMJ Case Rep. 2012 Nov 28;2012. pii: bcr2012007673. doi: 10.1136/bcr-2012-007673.
34. Shaikh M, Tahir H. Sacroilitis: an unusual cause for a common presentation. BMJ Case Rep. 2014 Sep 22;2014. pii: bcr2013203209. doi: 10.1136/bcr-2013-203209
35. Tahir H, Mease P, McInnes I, Kirkham B, Kavanaugh A et al. Secukinumab, A Human Anti-Interleukin-17A Monoclonal Antibody, Improves Active Psoriatic Arthritis and Inhibits Radiographic Progression: Efficacy and Safety Data from a Phase 3 Randomized, Multicentre, Double-Blind, Placebo-Controlled Study. Rheumatology (2015) 54 (suppl 1): i137-i138 doi:10.1093/rheumatology/kev089.115
36. Adshead R, Chua I, Donnelly SP, Tahir H. Ethnic Differences in Response to Anti-TNF in patients with Ankylosing Spondylitis Rheumatology (2015) 54 (suppl 1): i137-i138 doi:10.1093
37. Adshead R., Tahir H and Donnelly S. A best practice UK model for Axial Spondyloarthritis diagnosis and treatment. European Medical Journal: In press.
38. Raine C, Bubbear J, Tahir H. Polymyalgia Rheumatica. Foundation Year Journal 2015. Vol 9 (10);48-54
39. Choida V, Donnelly S, Bubbear J, Fattah Z, Tahir H. Reactive Arthritis. Foundation Year Journal 2015. Vol 9 (10);61-66
40. Kivitz A, Blanco R, Maradiago M, Sieper J, Tahir H, Readie A, Porter B. Secukinumab reduces signs and symptoms of active ankylosing spondylitis: Results from a 16 week, ransomised, placebo controlled phase 3 trial (Measure 3). PANLAR abstract 2016
41. Zamani O, Combe B, Tony HP, Burson JS, Tahir H, Larsen E, Smolen J. Efficacy and safety of baricitinib in patients with active rheumatoid arthritis and inadequate response to TNFi: summary results from the 24 week phase 3 RA –BEACON study. Rheumatol 2016
42. Raine C, Tahir H, Donnelly S. Aggressive vasculopathy causing extensive gangrene in a patient with anti-RNP positive limited scleroderma/inflammatory arthritis overlap syndrome. Rheumatol 2016
43. Etomi O, Chua I, Donnelly S, Tahir H. A survey of biologic prescribing habits amongst rheumatologists in London. Rheumatol 2016
44. Kavanagh A, Mease P, Reimold A, Tahir H, Rexh J, Mpofu S. Secukinumab provides sustained imptovements in the signs and symptoms of active psoriatic arthritis: 2 year efficacy and safety results from the phase 3 randomised, double blind, placebo controlled trial (FUTURE 1). Submitted Arthritis Care and Research
45. Wiland P, Dudler J, Veale D, Tahir H, Pederson R, Bukowski J, Vlahos B, Williams T, Gaylord S, Kotak S. The impact of withdrawn Etanercept-Methotrexate therapy on patient-reported outcomes in patients with early rheumatoid arthritis. Accepted Journal of Rheumatology
46. Omid Zamani, Bernard Combe, Hans-Peter Tony, Juan Sanchez Burson, Hasan Tahir, Mikkel Østergaard, Beatrice Augendre-Ferrante, Anke Beselin, Esbjörn Larsson, Marta Casillas, and Josef Smolen. Efficacy and Safety of Baricitinib in Patients with Active Rheumatoid Arthritis and Inadequate Response to Tumour Necrosis Factor Inhibitors: Summary Results from the 24-Week Phase III RA-Beacon Study. Rheumatology. 2016;55(suppl 1)
47. Omid Zamani, Bernard Combe, Hans-Peter Tony, Juan Sanchez Burson, Hasan Tahir, Mikkel Østergaard, Beatrice Augendre-Ferrante, Anke Beselin, Esbjörn Larsson, Marta Casillas, Josef Smolen. EFICACIA Y SEGURIDAD DE BARICITINIB EN PACIENTES CON ARTRITIS REUMATOIDE ACTIVA Y RESPUESTA INADECUADA A FARMACOS ANTIRREUMATICOS MODIFICADORES DE LA ENFERMEDAD CONVENCIONALES (FAMEs): RESUMEN DE LOS RESULTADOS DEL ESTUDIO DE FASE III RA-BUILD DE 24 SEMANAS. Sociedad Espanola de Reumatologia – XLII Congreso Nacional. 2016
48. Zamani O, Combe B, Tony HP, Burson JS, Tahir H, Østergaard M, Augendre-Ferrante B, Beselin A, Larsson E, Casillas M, Smolen J. Efficacy and safety of baricitinib in patients with active rheumatoid arthritis and inadequate response to tumour necrosis factor inhibitors: summary results from the 24-week phase 3 RA-BEACON study. Irish Society for Rheumatology Autumn congress, 2016
49. Wiland P, Dudler J, Veale D, Tahir H, Pedersen R, Bukowski J, Vlahos B, Williams T, Gaylord S, Kotak S. The Effect of Reduced or Withdrawn Etanercept-methotrexate Therapy on Patient-reported Outcomes in Patients with Early Rheumatoid Arthritis. J Rheumatol. 2016 Jul;43(7):1268-77. doi: 10.3899/jrheum.151179. Epub 2016 Jun 1.
50. Biro I, Etomi O, Barret J, Tahir H. Tick the tick: Arthritis in Lyme Disease. Foundation Year Journal 2017, vol 11 (2) 70-77
51. Pakozdi A, Lewis MJ, Tahir H. How to approach Vasculitis- a clinical guide. Foundation Year Journal 2017, vol 11 (2) 78- 87
52. Biro I, Etomi O, Pakozdi A, Tahir H. Management of common soft tissue disorders. Foundation Year Journal 2017, vol 11 (2) 88 -96
53. Wodehouse T, Poply K, Ramaswamy S, Snidvongs S, Bourke J, Tahir H, Ullrich K. A pilot study investigating whether quantitative sensory testing alters treatment bin patients with fibromyalgia. British Journal of Pain awaiting publication
54. Biro I, Bubbear J, Donnelly S, Fattah Z, Sarkodieh J, Ranganathan A, Tahir H. Teriparatide and vertebral fracture healing in Ankylosing Spondylitis. Trauma case reports 2017. vol 12, 34-39
55. Mease P, van der Heijde D, Landewé R, Mpofu S, Rahman P, Tahir H, Singhal A, Boettcher E, Navarra S, Meiser K, Readie A, Pricop L, Abrams K. Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study. Ann Rheum Dis. 2018 Mar 17. pii: annrheumdis-2017-212687. doi: 10.1136/annrheumdis-2017-212687.
56. Pavelka K, Kivitz A, Dokoupilova E, Blanco R, Maradiaga M, Tahir H, Pricop L, Andersson M, Readie A, Porter B. Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3. Arthritis Res Ther. 2017 Dec 22;19(1):285. doi: 10.1186/s13075-017-1490-y.
57. Tahir H, Deodhar A, Genovese M, Takeuchi T, Aelion J, Van den Bosch F, Haemmerle S, Richards HB. Secukinumab in Active Rheumatoid Arthritis after Anti-TNFα Therapy: A Randomized, Double-Blind Placebo-Controlled Phase 3 Study.Rheumatol Ther. 2017 Dec;4(2):475-488. doi: 10.1007/s40744-017-0086-y. Epub 2017 Nov 14.
58. Tahir H, Biro I, Donnelly S, Greenwood M. Randomised, prospective, non-blinded pilot study comparing the effect of intramuscular steroid injections and intralesional steroid injections in the management of tennis elbow.BMJ Open Sport Exerc Med. 2017 Feb 10;2(1):e000126. doi: 10.1136/bmjsem-2016-000126. eCollection 2016.
59. Wiland P, Dudler J, Veale D, Tahir H, Pedersen R, Bukowski J, Vlahos B, Williams T, Gaylord S, Kotak S Dr. Wiland, et al, reply. J Rheumatol. 2017 Feb;44(2):259. doi: 10.3899/jrheum.161405.
60. Kavanaugh A, Mease PJ, Reimold AM, Tahir H, Rech J, Hall S, Geusens P, Wang Z, Pricop L, Mpofu S; FUTURE-1 Study Group. Secukinumab for Long-Term Treatment of Psoriatic Arthritis: A Two-Year Followup From a Phase III, Randomized, Double-Blind Placebo-Controlled Study. Arthritis Care Res (Hoboken). 2017 Mar;69(3):347-355. doi: 10.1002/acr.23111.
61. Tahir H. Novel therapies in ankylosing spondylitis – from clinical trials to clinical practice. Submitted Rheumatology.
62. Mease P, Brodie G, Kavanagh A, Reimold A, Tahir H, Hall S, Geusens P, Pellet P, Delicha E, Mpofu S, Pricop L. Secukinumab in the treatment of psoriatic arthritis: Efficacy and safety results through 3 years from the year 1 extension of the phase 3 Future 1 trial. Submitted The Journal of Rheumatology 2017-1374.R1.
63. Pakozdi A & Tahir H. Comment on BSR and BHPR guideline for the prescription and monitoring of non-biologic disease modifying anti-rheumatic drugs. Rheumatology Advances in Practice 2017;0:1-2 doi:10. 1093/rap/rkx009
64. Pavelka K, Kivitz A, Dokoupilova E, Blanco R, Maradiaga M, Tahir H, et al. Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3.Arthritis Res Ther. 2017 Dec 22;19(1):285.
65. Tahir H, Deodhar A, Genovese M, Takeuchi T, Aelion J, Van den Bosch F, Haemmerle S, Richards HB. Secukinumab in Active Rheumatoid Arthritis after Anti-TNFα Therapy: A Randomized, Double-Blind Placebo-Controlled Phase 3 Study.Rheumatol Ther. 2017 Dec;4(2):475-488.
66. Tahir H, Biro I, Donnelly S, Greenwood M. Randomised, prospective, non-blinded pilot study comparing the effect of intramuscular steroid injections and intralesional steroid injections in the management of tennis elbow.BMJ Open Sport Exerc Med. 2017 Feb 10;2(1)
67. Kavanaugh A, Mease PJ, Reimold AM, Tahir H, et al. FUTURE-1 Study Group. Secukinumab for Long-Term Treatment of Psoriatic Arthritis: A Two-Year Followup From a Phase III, Randomized, Double-Blind Placebo-Controlled Study.Arthritis Care Res (Hoboken). 2017 Mar;69(3):347-355.
68. Pavelka K, Kivitz A, Dokoupilova E, Blanco R, Maradiaga M, Tahir H, et al. Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3.Arthritis Res Ther. 2017 Dec 22;19(1):285.
69. Biro I, Bubbear J, Donnelly S, Fattah Z, Sarkodieh J, Ranganathan A, Tahir H. Teriparatide and vertebral fracture healing in Ankylosing Spondylitis.Trauma Case Rep. 2017 Nov 8;12:34-39.
70. Tahir H. Therapies in ankylosing spondylitis – from clinical trials to clinical practice. Rheumatology 2018 Aug 1;57 (suppl 6)
71. Raine C, Canning B, Marks J, Donnelly S, Ong V, Tahir H. Severe gangrene in a patient with anti-RNP positive limited cutaneous systemic sclerosis/rheumatoid arthritis overlap syndrome caused by vasculopathy and vasculitis. Eur J Rheumatol. 2018 Dec;5(4):269-271.
72. Mease PJ, Kavanaugh A, Reimold A, Tahir H, Rech J et al. Secukinumab in the treatment of psoriatic arthritis: efficacy and safety results through 3 years from the year 1 extension of the randomised phase III FUTURE 1 trial.RMD Open. 2018 Aug 13;4(2)
73. Wodehouse T, Poply K, Ramaswamy S, Bourke J, Tahir H, et al. A pilot study investigating whether quantitative sensory testing alters after treatment in patients with fibromyalgia.Br J Pain. 2018 Nov;12(4):250-256.
74. Mease P, van der Heijde D, Landewé R, Mpofu S, Rahman P, Tahir H, et al. Secukinumab improves active psoriatic arthritis symptoms and inhibits radiographic progression: primary results from the randomised, double-blind, phase III FUTURE 5 study.Ann Rheum Dis. 2018 Mar 17.
75. Kivitz AJ, Nash P, Tahir H, Everding A, Mann H, Kaszuba A, Pellet P, Widmer A, Pricop L, Abrams K.Efficacy and Safety of Subcutaneous Secukinumab 150 mg with or Without Loading Regimen in Psoriatic Arthritis: Results from the FUTURE 4 Study Rheumatol Ther. 2019 Sep;6(3):393-407.
76. Mease PJ, Smolen JS, Behrens F, Nash P, Liu Leage S, Li L, Tahir H, Gooderham M, Krishnan E, Liu-Seifert H, Emery P, Pillai SG, Helliwell PS; SPIRIT H2H study group. A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-na�ve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. Ann Rheum Dis. 2020 Jan;79(1):123-131. doi: 10.1136/annrheumdis-2019-215386. Epub 2019 Sep 28. PMID: 31563894; PMCID: PMC6937408.
77. Mease PJ, Kavanaugh A, Reimold A, Tahir H, Rech J, Hall S, Geusens P, Pellet P, Delicha EM, Pricop L, Mpofu S; FUTURE 1 study group. Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Psoriatic Arthritis: Final 5-year Results from the Phase 3 FUTURE 1 Study. ACR Open Rheumatol. 2020 Jan;2(1):18-25. doi: 10.1002/acr2.11097. Epub 2019 Nov 14. PMID: 31943974;PMCID: PMC6957920.
78. van der Heijde D, Mease PJ, Landew� RBM, Rahman P, Tahir H, Singhal A, Boettcher E, Navarra S, Zhu X, Ligozio G, Readie A, Mpofu S, Pricop L. Secukinumab provides sustained low rates of radiographic progression in psoriatic arthritis: 52-week results from a phase 3 study, FUTURE 5. Rheumatology (Oxford). 2020 Jun 1;59(6):1325-1334. doi: 10.1093/rheumatology/kez420. PMID: 31586420; PMCID: PMC7244782.
79. Smolen JS, Mease P, Tahir H, Schulze-Koops H, de la Torre I, Li L, Hojnik M, Sapin C, Okada M, Caporali R, Gratac�s J, Goupille P, Liu Leage S, Pillai S, Nash P. Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis na�ve to biological disease-modifying antirheumatic drug: final results by week 52. Ann Rheum Dis. 2020 Oct;79(10):1310-1319. doi: 10.1136/annrheumdis-2020-217372. Epub 2020 Jul 13. PMID: 32660977; PMCID: PMC7509529.
80. Amani L, Warraich R, Patel N, Tahir H. COVID-19 and rheumatology: is shielding really necessary? Br J Hosp Med (Lond). 2020 Jun 2;81(6):1-3. doi: 10.12968/hmed.2020.0284. Epub 2020 Jun 3. PMID: 32589537.
81. Pavelka K, Kivitz AJ, Dokoupilova E, Blanco R, Maradiaga M, Tahir H, Wang Y, Porter BO, Stefanska A, Richards HB, Rohrer S; MEASURE 3 study group. Secukinumab 150/300 mg Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis: 3-Year Results from the Phase 3 MEASURE 3 Study. ACR Open Rheumatol. 2020 Feb;2(2):119-127. doi: 10.1002/acr2.11102. Epub 2020 Jan 20. PMID: 31957970; PMCID: PMC7011421.
82. Adshead R, Donnelly S, Knight P, Tahir H. Axial Spondyloarthritis: Overcoming the Barriers to Early Diagnosis-an Early Inflammatory Back Pain Service. Curr Rheumatol Rep. 2020 Aug 17;22(10):59. doi: 10.1007/s11926-020-00923-6. PMID: 32808099.
83. Warraich R, Amani L, Mediwake R, Tahir H. Immunosuppression drug advice and COVID-19: are we doing more harm than good? Br J Hosp Med (Lond). 2020 Jun 2;81(6):1-3. doi: 10.12968/hmed.2020.0312. Epub 2020 Jun 22. PMID: 32589546.
84. Kivitz AJ, Nash P, Tahir H, Everding A, Mann H, Kaszuba A, Pellet P, Widmer A, Pricop L, Abrams K. Efficacy and Safety of Subcutaneous Secukinumab 150mg with or Without Loading Regimen in Psoriatic Arthritis: Results from the FUTURE 4 Study. Rheumatol Ther. 2019 Sep;6(3):393-407. doi: 10.1007/s40744-019-0163-5. Epub 2019 Jun 21. PMID: 31228101; PMCID: PMC6702584.
85. Mease PJ, Kavanaugh A, Reimold A, Tahir H, Rech J, Hall S, Geusens P, Pellet P, Delicha EM, Pricop L, Mpofu S; FUTURE 1 study group. Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Psoriatic Arthritis: Final 5-year Results from the Phase 3 FUTURE 1 Study. ACR Open Rheumatol. 2020 Jan;2(1):18-25. doi: 10.1002/acr2.11097. Epub 2019 Nov 14. PMID: 31943974; PMCID: PMC6957920.
86. Baraliakos X, Braun J, Deodhar A, Poddubnyy D, Kivitz A, Tahir H, Van den Bosch F, Delicha EM, Talloczy Z, Fierlinger A. Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study. RMD Open. 2019 Sep 3;5(2):e001005. doi: 10.1136/rmdopen-2019-001005. PMID: 31565244; PMCID: PMC6744073.
87. Lisa Amani, Rabia Warraich, Jeffrey Lee, Tahir H; Steroid Injections & COVID-19: Are Specialists Justified in Defying the Guidelines? Int. J. Clin. Rheumatol. (2020) 15(4), 129-130 Priyanka Nemchand, Hasan Tahir, Rapti Mediwake, Jeffrey Lee Cytokine storm and use of anakinra in a patient with COVID-19 BMJ Case Rep 2020;13: e237525. doi:10.1136/bcr- 2020-237525
88. Tahir H, Moorthy A, Chan A. Impact of Secukinumab on Patient-Reported Outcomes in the Treatment of Ankylosing Spondylitis: Current Perspectives. Open Access Rheumatol. 2020; 12:277-292 https://doi.org/10.2147/OARRR.S265806
89. Byravan S, Fardanesh A, Tahir H, Moorty A. Digital health strategies in the war against COVID-19 and beyond, British Journal of Hospital Medicine, 81(12), pp. 1 3. doi: 10.12968/hmed.2020.0684.
90. Quek E, Tahir H, Kumar P, Hastings R, Jha R. Treatment of COVID-19: a review of current and prospective pharmacotherapies. Br J Hosp Med (Lond). 2021 Mar 2;82(3):1-9. doi: 10.12968/hmed.2021.0112. Epub 2021 Mar 12. PMID: 33792391.
91. Tahir H, Grewal S. Current unmet needs and emerging novel pharmacotherapies in psoriatic arthritis. Expert Opin Pharmacother. 2021 Dec 3:1-4. doi: 10.1080/14656566.2021.2006184. Epub ahead of print. PMID: 34787511.
92. Tahir H, Byravan S, Fardanesh A, Moorthy A. Promising Treatment Options for Axial Spondyloarthritis: An Overview of Experimental Pharmacological Agents. J Exp Pharmacol. 2021 Jul 2;13:627-635. doi: 10.2147/JEP.S262340. PMID: 34257507; PMCID: PMC8269276.
93. RECOVERY Collaborative Group. Aspirin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2022 Jan 8;399(10320):143-151. doi: 10.1016/S0140-6736(21)01825-0. Epub 2021 Nov 17. PMID: 34800427; PMCID: PMC8598213.
94. Coates LC, Pillai SG, Tahir H, Valter I, Chandran V, Kameda H, Okada M, Kerr L, Alves D, Park SY, Adams DH, Gallo G, Hufford MM, Hojnik M, Mease PJ, Kavanaugh A; SPIRIT-P3 Study Group. Withdrawing Ixekizumab in Patients With Psoriatic Arthritis Who Achieved Minimal Disease Activity: Results From a Randomized, Double-Blind Withdrawal Study. Arthritis Rheumatol. 2021 Sep;73(9):1663-1672. doi: 10.1002/art.41716. Epub 2021 Aug 6. PMID: 33682378; PMCID: PMC8457232.
95. Mease PJ, Landewé R, Rahman P, Tahir H, Singhal A, Boettcher E, Navarra S, Readie A, Mpofu S, Delicha EM, Pricop L, van der Heijde D. Secukinumab provides sustained improvement in signs and symptoms and low radiographic progression in patients with psoriatic arthritis: 2-year (end-of-study) results from the FUTURE 5 study. RMD Open. 2021 Jul;7(2):e001600. doi: 10.1136/rmdopen-2021-001600. PMID: 34330846; PMCID: PMC8327842.
96. Taribagil P, Creer D, Tahir H. ‘Long COVID’ syndrome. BMJ Case Rep. 2021 Apr 19;14(4):e241485. doi: 10.1136/bcr-2020-241485. PMID: 33875508; PMCID: PMC8057566
97. Byravan S, Fardanesh A, Tahir H, Moorthy A. Emerging COVID-19 vaccines: A rheumatology perspective. Int J Rheum Dis. 2021 Feb;24(2):144-146. doi: 10.1111/1756-185X.14048. PMID: 33523564.
98. Fardanesh A, Byravan S, Moorthy A, Tahir H. COVID-19 and rheumatology: Reflecting on the first wave and preparing for the second wave. Int J Rheum Dis. 2021 Jan;24(1):7-9. doi: 10.1111/1756-185X.14062. PMID: 33459529.
99. Quek E, Tahir H. COVID-19 vaccines: what happened to evidence-based medicine? Br J Hosp Med (Lond). 2021 Feb 2;82(2):1-4. doi: 10.12968/hmed.2021.0047. Epub 2021 Feb 3. PMID: 33646036
100. Mease PJ, Landewé R, Rahman P, Tahir H, Singhal A, Boettcher E, Navarra S, Readie A, Mpofu S, Delicha EM, Pricop L, van der Heijde D. Secukinumab provides sustained improvement in signs and symptoms and low radiographic progression in patients with psoriatic arthritis: 2-year (end-of-study) results from the FUTURE 5 study. RMD Open. 2021 Jul;7(2):e001600. doi: 10.1136/rmdopen-2021-001600. PMID: 34330846; PMCID: PMC8327842.
101. Taribagil P, Creer D, Tahir H. ‘Long COVID’ syndrome. BMJ Case Rep. 2021 Apr 19;14(4):e241485. doi: 10.1136/bcr-2020-241485. PMID: 33875508; PMCID: PMC8057566
102. Mease PJ, Smolen JS, Behrens F, Nash P, Liu Leage S, Li L, Tahir H, Gooderham, M, Krishnan E, Liu-Seifert H, Emery P, Pillai SG, Helliwell PS; SPIRIT H2H study group. A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. Ann Rheum Dis. 2020 Jan;79(1):123-131. doi: 10.1136/annrheumdis-2019-215386. Epub 2019 Sep 28. PMID: 31563894; PMCID: PMC6937408.
103. Mease PJ, Kavanaugh A, Reimold A, Tahir H, Rech J, Hall S, Geusens P, Pellet P, Delicha EM, Pricop L, Mpofu S; FUTURE 1 study group. Secukinumab Provides Sustained Improvements in the Signs and Symptoms of Psoriatic Arthritis: Final 5-year Results from the Phase 3 FUTURE 1 Study. ACR Open Rheumatol. 2020 Jan;2(1):18-25. doi: 10.1002/acr2.11097. Epub 2019 Nov 14. PMID: 31943974; PMCID: PMC6957920.
104. van der Heijde D, Mease PJ, Landewé RBM, Rahman P, Tahir H, Singhal A, Boettcher E, Navarra S, Zhu X, Ligozio G, Readie A, Mpofu S, Pricop L. Secukinumab provides sustained low rates of radiographic progression in psoriatic arthritis: 52-week results from a phase 3 study, FUTURE 5. Rheumatology (Oxford). 2020 Jun 1;59(6):1325-1334. doi: 10.1093/rheumatology/kez420. PMID: 31586420; PMCID: PMC7244782.
105. Smolen JS, Mease P, Tahir H, Schulze-Koops H, de la Torre I, Li L, Hojnik M, Sapin C, Okada M, Caporali R, Gratacós J, Goupille P, Liu Leage S, Pillai S, Nash P. Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naïve to biological disease-modifying antirheumatic drug: final results by week 52. Ann Rheum Dis. 2020 Oct;79(10):1310-1319. doi: 10.1136/annrheumdis-2020-217372. Epub 2020 Jul 13. PMID: 32660977; PMCID: PMC7509529.
106. Amani L, Warraich R, Patel N, Tahir H. COVID-19 and rheumatology:is shielding really necessary? Br J Hosp Med (Lond). 2020 Jun 2;81(6):1-3. doi: 10.12968/hmed.2020.0284. Epub 2020 Jun 3. PMID: 32589537.
107. Pavelka K, Kivitz AJ, Dokoupilova E, Blanco R, Maradiaga M, Tahir H, Wang Y, Porter BO, Stefanska A, Richards HB, Rohrer S; MEASURE 3 study group. Secukinumab 150/300 mg Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis: 3-Year Results from the Phase 3 MEASURE 3 Study. ACR Open Rheumatol. 2020 Feb;2(2):119-127. doi: 10.1002/acr2.11102. Epub 2020 Jan 20. PMID: 31957970; PMCID: PMC7011421.
108. Adshead R, Donnelly S, Knight P, Tahir H. Axial Spondyloarthritis: Overcoming the Barriers to Early Diagnosis-an Early Inflammatory Back Pain Service. Curr Rheumatol Rep. 2020 Aug 17;22(10):59. doi: 10.1007/s11926-020-00923-6. PMID: 32808099.
109. Warraich R, Amani L, Mediwake R, Tahir H. Immunosuppression drug advice and COVID-19: are we doing more harm than good? Br J Hosp Med (Lond). 2020 Jun 2;81(6):1-3. doi: 10.12968/hmed.2020.0312. Epub 2020 Jun 22. PMID: 32589546.
110. Kivitz AJ, Nash P, Tahir H, Everding A, Mann H, Kaszuba A, Pellet P, Widmer A, Pricop L, Abrams K. Efficacy and Safety of Subcutaneous Secukinumab 150 mg with or Without Loading Regimen in Psoriatic Arthritis: Results from the FUTURE 4 Study. Rheumatol Ther. 2019 Sep;6(3):393-407. doi: 10.1007/s40744-019-0163-5. Epub 2019 Jun 21. PMID: 31228101; PMCID: PMC6702584.
111. Baraliakos X, Braun J, Deodhar A, Poddubnyy D, Kivitz A, Tahir H, Van den Bosch F, Delicha EM, Talloczy Z, Fierlinger A. Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study. RMD Open. 2019 Sep 3;5(2):e001005. doi: 10.1136/rmdopen-2019-001005. PMID: 31565244; PMCID: PMC6744073.
112. Priyanka Nemchand, Hasan Tahir, Rapti Mediwake, Jeffrey Lee.Cytokine storm and use of anakinra in a patient with COVID-19 BMJ Case Rep 2020;13: e237525. doi:10.1136/bcr-2020-237525
113. Byravan S, Fardanesh A, Tahir H, Moorty A. ‘Digital health strategies in the war against COVID-19 and beyond’, British Journal of Hospital Medicine, 81(12), pp. 1–3. doi: 10.12968/hmed.2020.0684.
114. Byravan S, Fardanesh A, Tahir H, Moorthy A. Emerging COVID-19 vaccines: A rheumatology perspective. Int J Rheum Dis. 2021 Feb;24(2):144-146. doi: 10.1111/1756-185X.14048. PMID: 33523564.
115. Fardanesh A, Byravan S, Moorthy A, Tahir H. COVID-19 and rheumatology: Reflecting on the first wave and preparing for the second wave. Int J Rheum Dis. 2021 Jan;24(1):7-9. doi: 10.1111/1756-185X.14062. PMID: 33459529.
116. Quek E, Tahir H. COVID-19 vaccines: what happened to evidence-based medicine? Br J Hosp Med (Lond). 2021 Feb 2;82(2):1-4. doi: 10.12968/hmed.2021.0047. Epub 2021 Feb 3. PMID: 33646036
117. Amani L, Warraich R, Patel N, Tahir H. COVID-19 and rheumatology: is shielding really necessary? Br J Hosp Med (Lond). 2020 Jun 2;81(6):1-3. doi: 10.12968/hmed.2020.0284. Epub 2020 Jun 3. PMID: 32589537.
118. Ahmed O, Krishnamurthy V, Kaba RA, Tahir H. The management of cardiovascular disease risk in patients with rheumatoid arthritis. Expert Opin Pharmacother. 2022 Jun;23(8):947-958. doi: 10.1080/14656566.2022.2076594. PMID: 35575484.
119. Coates LC, Garrood T, Gullick N, Helliwell P, Kent T, Marks J, Tillett W, Kaur-Papadakis D, Tahir H, van Haaren S, McInnes I. Upadacitinib response rates in patients with psoriatic arthritis enrolled in the SELECT-PsA-1 and SELECT-PsA-2 trials assessed according to modified PsARC. Rheumatology (Oxford). 2022 Dec 23;62(1):e1-e3. doi: 10.1093/rheumatology/keac388. PMID: 35799375.
120. Gregory WJ, Kaur J, Bamford S, Tahir H. A Survey of Diagnostic Delay in Axial Spondyloarthritis Across Two National Health Service (NHS) Rheumatology Services. Cureus. 2022 Mar 30;14(3):e23670. doi: 10.7759/cureus.23670. PMID: 35510018; PMCID: PMC9060761.
121. Bennett B, Tahir H, Ganguly S, Moorthy A. An update on the considerations for patients with rheumatic disease being treated with rituximab during the COVID-19 pandemic and the potential drug treatment strategies. Expert Opin Pharmacother. 2022 Oct;23(15):1695-1700. doi: 10.1080/14656566.2022.2131395. Epub 2022 Oct 5. PMID: 36180063.
122. Jubber A, Woodward J, Tahir H, Moorthy A. Venous thromboembolism risk with Janus kinase inhibitors: Is it a class wide effect? Expert Opin Drug Saf. 2022 Aug;21(8):1005-1007. doi: 10.1080/14740338.2022.2100343. Epub 2022 Jul 13. PMID: 35818715.
123. Quek E, Tahir H, Kumar P, Hastings R, Jha R. Treatment of COVID-19: a review of current and prospective pharmacotherapies. Br J Hosp Med (Lond). 2021 Mar 2;82(3):1-9. doi: 10.12968/hmed.2021.0112. Epub 2021 Mar 12. PMID: 33792391.
124. Tahir H, Grewal S. Current unmet needs and emerging novel pharmacotherapies in psoriatic arthritis. Expert Opin Pharmacother. 2021 Dec 3:1-4. doi: 10.1080/14656566.2021.2006184. Epub ahead of print. PMID: 34787511.
125. Tahir H, Byravan S, Fardanesh A, Moorthy A. Promising Treatment Options for Axial Spondyloarthritis: An Overview of Experimental Pharmacological Agents. J Exp Pharmacol. 2021 Jul 2;13:627-635. doi: 10.2147/JEP.S262340. PMID: 34257507; PMCID: PMC8269276.
126. Watts S, Nagib LG, Bamford S, Sheraz A, Tahir H. A Patient Survey Exploring the Burden of Inflammatory Back Pain in Patients With Known Psoriasis. Cureus. 2024 Jan 9;16(1):e51968. doi: 10.7759/cureus.51968. PMID: 38333437; PMCID: PMC10853012.
127. Nageswaran P, Ahmed S, Tahir H. Review of phase 2/3 trials in polymyalgia rheumatica and giant cell arteritis. Expert Opin Emerg Drugs. 2024 Jan 5:1-13. doi: 10.1080/14728214.2024.2303093. Epub ahead of print. PMID: 38180809.
128. Bennett B, Tahir H, Solanki K, Ali N. An update on MRONJ in patients with Osteoporosis. EMJ Rheumatol. 2023; DOI/10.33590/emjrheumatol/10300262.
129. Jubber A, Tahir H, Moorthy A. Clinical efficacy of JAK inhibitors on enthesitis in spondyloarthropathy: A scoping literature review. Musculoskeletal Care. 2023 Dec;21(4):1195-1203. doi: 10.1002/msc.1802. Epub 2023 Jul 28. Erratum in: Musculoskeletal Care. 2023 Sep 8;: PMID: 37501580.
130. Bamford S, Tahir H, Ladan Z, Hanumunthadu D. Patient Survey Exploring the Burden of Inflammatory Back Pain in Patients with Uveitis. Cureus. 2023 Apr 12;15(4):e37473. doi: 10.7759/cureus.37473. PMID: 37187633; PMCID: PMC10176535.